Literature DB >> 20087161

PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis.

Chandra Krishnan1, Roger A Warnke, Daniel A Arber, Yasodha Natkunam.   

Abstract

Peripheral T-cell lymphomas are a heterogeneous group that often requires the use of ancillary testing for accurate diagnosis. This is particularly applicable to the diagnosis of angiommunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma, unclassified (PTCLU), because of their histologic and immunophenotypic overlap with reactive lymphoid proliferations. Recently, immunohistochemistry for programmed death-1 (PD-1), a marker of follicular helper T cells, was shown to be sensitive in the detection of AITL and PTCLU. The sensitivity of this marker in reactive entities, however, has not been adequately evaluated. We confirm that PD-1 staining is a highly sensitive marker in the diagnosis of peripheral T-cell lymphomas: increased extrafollicular PD-1-positive cells were seen in 93% (76/82) of AITL, 62% (16/26) of PTCLU, and 11% (2/18) of anaplastic-lymphoma-kinase (ALK)-negative anaplastic large-cell lymphomas. The majority of reactive lymphadenopathies including Cat-scratch disease, Kikuchi lymphadenitis, Castleman disease, and reactive follicular hyperplasia showed no PD-1 staining outside follicles. Some reactive lymph nodes, showed increased extrafollicular PD-1-positive cells in a pattern similar to AITL and PTCLU, and include progressive transformation of germinal centers, viral lymphadenitis (Epstein-Barr virusand human immunodeficiency virus) and Rosai-Dorfman disease. This study shows that PD-1-positive cells may be increased in a number of settings other than T-cell lymphomas. We conclude that staining for PD-1 in reactive and atypical lymphadenopathies should be interpreted with caution and in the context of other ancillary immunophenotypic and molecular studies before a diagnosis of AITL or PTCLU is entertained.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087161      PMCID: PMC2819320          DOI: 10.1097/PAS.0b013e3181cc7e79

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  Peripheral T-cell lymphoma complicated by a proliferation of large B cells.

Authors:  J P Higgins; M van de Rijn; C D Jones; J L Zehnder; R A Warnke
Journal:  Am J Clin Pathol       Date:  2000-08       Impact factor: 2.493

2.  T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells.

Authors:  Tatyana Chtanova; Stuart G Tangye; Rebecca Newton; Nita Frank; Martin R Hodge; Michael S Rolph; Charles R Mackay
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

3.  Unique gene expression program of human germinal center T helper cells.

Authors:  Chang H Kim; Hyung W Lim; Jong R Kim; Lusijah Rott; Peter Hillsamer; Eugene C Butcher
Journal:  Blood       Date:  2004-06-22       Impact factor: 22.113

4.  Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells.

Authors:  Jehan Dupuis; Karine Boye; Nadine Martin; Christiane Copie-Bergman; Anne Plonquet; Bettina Fabiani; Anne-Catherine Baglin; Corinne Haioun; Marie-Hélène Delfau-Larue; Philippe Gaulard
Journal:  Am J Surg Pathol       Date:  2006-04       Impact factor: 6.394

5.  Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma.

Authors:  Hongbo Yu; Aliakbar Shahsafaei; David M Dorfman
Journal:  Am J Clin Pathol       Date:  2009-01       Impact factor: 2.493

6.  Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.

Authors:  David M Dorfman; Julia A Brown; Aliakbar Shahsafaei; Gordon J Freeman
Journal:  Am J Surg Pathol       Date:  2006-07       Impact factor: 6.394

7.  The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations.

Authors:  Brenton T Tan; Roger A Warnke; Daniel A Arber
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 8.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

9.  Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression.

Authors:  Ayoma Deepthi Attygalle; Charalampia Kyriakou; Jehan Dupuis; Karen Lynne Grogg; Timothy Charles Diss; Andrew Charles Wotherspoon; Shih Sung Chuang; José Cabeçadas; Peter Gershon Isaacson; Ming-Qing Du; Philippe Gaulard; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2007-07       Impact factor: 6.394

10.  Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics.

Authors:  Roger A Warnke; Dan Jones; Eric D Hsi
Journal:  Am J Clin Pathol       Date:  2007-04       Impact factor: 2.493

View more
  18 in total

1.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2010-06-02       Impact factor: 0.196

2.  Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.

Authors:  Arutselvan Natarajan; Aaron T Mayer; Robert E Reeves; Claude M Nagamine; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

3.  Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.

Authors:  Eric D Hsi; Jonathan Said; William R Macon; Scott J Rodig; Sarah L Ondrejka; Randy D Gascoyne; Elizabeth A Morgan; David M Dorfman; Matthew J Maurer; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

Review 4.  Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.

Authors:  Lorenzo Falchi
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 5.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 6.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08

7.  Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma: A Potential Diagnostic Pitfall.

Authors:  Caoimhe Egan; Camille Laurent; Julie C Alejo; Stefano Pileri; Elias Campo; Steven H Swerdlow; Miguel Piris; Wing C Chan; Roger Warnke; Randy D Gascoyne; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2020-05       Impact factor: 6.298

Review 8.  Treatment Advances in EBV Related Lymphoproliferative Diseases.

Authors:  Kebing Lv; Ting Yin; Min Yu; Zhiwei Chen; Yulan Zhou; Fei Li
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

Review 9.  Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.

Authors:  Xi Chen; Wanchun Wu; Wenwen Wei; Liqun Zou
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

Review 10.  How I Diagnose Angioimmunoblastic T-Cell Lymphoma.

Authors:  Yi Xie; Elaine S Jaffe
Journal:  Am J Clin Pathol       Date:  2021-06-17       Impact factor: 5.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.